Diane Bollens

High Rate of Virologic Suppression with Raltegravir plus Etravirine and Darunavir/Ritonavir among Treatment‐Experienced Patients Infected with Multidrug‐Resistant HIV: Results of the ANRS 139 TRIO Trial

Yazdan Yazdanpanah, Catherine Fagard, Diane Descamps et al. · Clinical Infectious Diseases · 2009 · 237 citations

Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial

Aurélien Dinh, Jacques Ropers, Clara Duran et al. · The Lancet · 2021 · 153 citations

Community-acquired Pneumonia, Critical Care Medicine, Antibiotics +7

Pulmonary Cryptococcosis: Localized and Disseminated Infections in 27 Patients with AIDS

M. C. Meyohas, Patricia Roux, Diane Bollens et al. · Clinical Infectious Diseases · 1995 · 132 citations

Relationship between HIV protease inhibitors and QTc interval duration in HIV‐infected patients: a cross‐sectional study

Bény Charbit, Arnaud Rosier, Diane Bollens et al. · British Journal of Clinical Pharmacology · 2008 · 47 citations · Full text

Steady-State Pharmacokinetics of Amprenavir Coadministered with Ritonavir in Human Immunodeficiency Virus Type 1-Infected Patients

Cécile Goujard, Isabelle Vincent, Jean‐Luc Meynard et al. · Antimicrobial Agents and Chemotherapy · 2002 · 36 citations · Full text